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Objective: The long-term results of the surgical treatment for patients with pulmo-
nary metastases from uterine malignancies were clarified.
Methods: A total of 133 patients who underwent pulmonary metastasectomy for
uterine malignancies were enrolled in the Metastatic Lung Tumor Study Group of
Japan between March 1984 and February 2002. These patients constituted the study
population, and their clinical, pathologic, and prognostic data were retrospectively
analyzed.
Results: The morbidity and mortality rates related to the operation were minimal
(1% and 1%, respectively). The 5- and 10-year survivals after the surgical resection
in all cases were 54.6% and 44.9%, respectively. The 5-year survivals for each
histologic type were estimated to be 46.8% for squamous cell carcinoma (n  58),
40.3% for cervical adenocarcinoma (n  13), 75.7% for endometrial adenocarci-
noma (n  23), 86.5% for choriocarcinoma (n  16), and 37.9% for leiomyosar-
coma (n 11). In the univariate analysis, the following were shown to be associated
with poor survival: primary tumor in the cervix, short disease-free interval (12
months), large number of resected metastases (4), and large tumor size (3 cm).
After mutual adjustment, short disease-free interval (12 months) alone was related
to risk of death (hazard ratio  2.26, 95% confidence interval  1.06-4.78) for 105
patients, excluding patients with choriocarcinoma and miscellaneous histologic
types.
Conclusion: Pulmonary metastasectomy for uterine malignancies is a safe and
acceptable treatment to improve survival. Patients with a disease-free interval of 12
months or more are good candidates for this treatment if there is adequate control
of the primary tumor without extrapulmonary metastasis.
Pulmonary metastasectomy has been widely adopted for treatment inproperly selected patients with metastases isolated to the lung. Sur-vival after pulmonary resections varies among different primary tu-mor types.1 Trek2 first reported a patient who underwent pulmonaryresection for metastatic uterine adenocarcinoma in 1930. After thatreport, some investigators reported patients with uterine cancer with
pulmonary metastases, treated with or without resection.3-6 However, the surgical
results of pulmonary metastasectomy for uterine malignancies have been inadequate
in large series of patients. This study analyzes the clinical and pathologic informa-
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tion and prognostic variables of a large number of patients
undergoing pulmonary resection for metastatic uterine ma-
lignancies.
Patients and Methods
Between March 1984 and February 2002, 133 female patients who
underwent pulmonary resection for metastatic uterine malignan-
cies were registered in the Metastatic Lung Tumor Study Group of
Japan. The clinical, pathologic, and prognostic data were obtained
from the registry in a retrospective fashion. The selection of
patients for surgical treatment or the operative procedure depended
on each institution. There was no unified guideline for the opera-
tive approach. Follow-up was performed at each institution. Op-
erative mortality was defined as death within the first 30 days
postoperatively or during hospitalization.
Survival was measured from the initial pulmonary metastasec-
tomy until death or the last date of the follow-up (October 11,
2002), and the data were reported as mean and 95% confidence
intervals (CIs). The survival curves according to selected clinical
and pathologic characteristics were calculated with the Kaplan-
Meier method,7 and comparisons among the curves were made
with the log-rank test. Subsequently, we performed a multivariable
analysis to clarify an independent effect of each characteristic on
survival using a Cox proportional hazards model.8
Results
The mean age of the patients at thoracotomy was 56.4 years
(range 26-80 years). The patients’ characteristics are shown
in Table 1. A total of 77 of the 133 patients (58%) under-
went surgery for a single metastasis, and 23 patients (17%)
underwent surgery for 4 or more metastases. The disease-
free interval (DFI), defined as the time between treatment of
the primary site and detection of lung metastases, ranged
from 0 to 243 months. Pulmonary metastases were detected
simultaneously with the primary tumor (DFI  0) in 8
patients (6%). The DFI was less than 12 months in 23
patients (17%), whereas it was more than 36 months in 60
patients (45%). Thirty-eight patients (29%) underwent bi-
lateral thoracotomy for complete tumor removal, 18 of
whom underwent staged operations. Repeated metastasec-
tomy was distinguished from a staged operation. Of 12
patients undergoing repeated metastasectomy for recurrent
disease after the initial pulmonary resection, 2 patients
underwent 3 metastasectomies and 1 patient underwent 4
metastasectomies. Forty-five patients (34%) underwent me-
diastinal or hilar lymphadenectomy, or both. Among them,
16 patients had pathologically positive lymph nodes. Eight
patients (6%) had extrapulmonary metastases at the time of
lung metastasectomy.
There was 1 postoperative death as the result of cardiac
infarction (mortality rate 1%). In the total of 166 operations
in the 133 patients, there were 2 postoperative major com-
plications (morbidity rate 1%): wound infection and liver
dysfunction.
Median follow-up time was 40 months with a range of 0
to 220 months, and overall cumulative 5-year and 10-year
survivals in the 133 patients were 54.6% (95% CI, 45.9%-
63.9%) and 44.9% (95% CI, 34.3%-55.5%), respectively.
The patients with a primary tumor in the cervix had a 5-year
survival of 45.7% (95% CI, 33.2%-58.2%), and the patients
with a tumor in the body had a 5-year survival of 66.3%
(95% CI, 53.0%-79.5%) (P  .01). The 5-year survivals in
different histologic types were calculated as 46.8% (95%
CI, 32.3%-61.2%) in squamous cell carcinoma, 40.3%
(95% CI, 11.6%-69.0%) in cervical adenocarcinoma, 75.7%
TABLE 1. Characteristics of 133 patients who underwent
surgical resection for pulmonary metastases from uterine
malignancies
Characteristic
No. of
patients
Histology
Cervix
Squamous cell carcinoma 58
Adenocarcinoma 13
Others 5
Body
Endometrial adenocarcinoma 23
Choriocarcinoma 16
Leiomyosarcoma 11
Others 7
Disease-free interval (mo)*
0 8
1-11 23
12-35 38
36 60
Unknown 4
Number of resected metastases
1 77
2-3 31
4 23
Unknown 2
Tumor size (cm)
3.0 71
3.0 52
Unknown 10
Surgical approach
Unilateral 95
Bilateral 38
Type of resection (second resection
of the staged operation)†
Pneumonectomy 3 (0)
Bilobectomy 3 (0)
Lobectomy 60 (1)
Wedge resection and/or
segmentectomy
67 (17)
Lymphadenectomy
Performed 45
Not performed 49
Unknown 39
*Disease-free interval was defined as time from the treatment of primary
tumor to lung metastases detection.
†The number of resection type does not include those of repeated metas-
tasectomy.
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(95% CI, 56.7%-94.6%) in endometrial adenocarcinoma,
86.5% (95% CI, 69.1%-100%) in choriocarcinoma, and
37.9% (95% CI, 6.3%-69.5%) in leiomyosarcoma (Figure
1). Among patients with pulmonary metastases from cervi-
cal cancers, there was no significant difference in survival
between the 2 histologic types of adenocarcinoma and squa-
mous cell carcinoma (P  .92). On the contrary, among
patients with body tumors, leiomyosarcoma was associated
with worse outcome in comparison with adenocarcinoma
(P  .02).
Patients with a DFI of 12 months or more achieved a
5-year survival of 59.8% (95% CI, 49.3%-70.3%), whereas
patients with a DFI of less than 12 months achieved a 5-year
survival of 36.8% (95% CI, 17.3%-56.3%) (P  .02) (Fig-
ure 2). Excluding 8 patients with pulmonary metastases
detected simultaneously with the primary tumor, those sur-
vivals were still significantly different (59.8% and 17.1%,
respectively) (P  .0001). Patients with a DFI of more than
36 months demonstrated no additional survival advantage
compared with those with a DFI between 12 and 36 months
(5-year survivals, 56.9% and 52.8%, respectively) (P  .37).
A significant difference in survival according to the
number of resected metastases is shown in Figure 3. The
5-year survivals of patients with 3 or less metastases and 4
or more metastases were 58.5% (95% CI, 48.4%-68.5%)
and 32.1% (95% CI, 9.1%-55.1%), respectively (P  .03).
Patients with a single metastasis (n  77) achieved a 5-year
survival of 60.5% (95% CI, 48.9%-72.0%). However,
among the patients with a DFI of more than 12 months, the
13 patients with more than 4 metastases achieved a 5-year
survival of 49.2%, and the survival was not significantly
different from that of the other 85 patients with 3 or less
lesions (P  .88).
In regard to the resected tumor size, there was a signif-
icant difference between patients whose tumors had a maxi-
mum diameter of less than 3 cm and patients whose tumors had
a maximum diameter of 3 cm or more (P  .01) (Figure 4).
Lymph node dissection itself did not statistically affect
prolonged survival (P  .76). Among the 45 patients who
underwent lymphadenectomy, those with positive lymph
nodes (n 16) had poorer survival than those with negative
lymph nodes (5-year survival, 30.3% vs 60.2%). However,
there was no significant difference in the survival between
these 2 groups (P  .25).
Eight patients (6%) with extrapulmonary metastasis had
a poorer prognosis than the patients with no extrapulmonary
metastasis (5-year survival, 43.8% vs 57.4%), but the sur-
vival between the 2 groups was not statistically different
(P  .88).
Multivariable analysis was performed for patients with
cervical squamous cell carcinoma, cervical adenocarci-
noma, endometrial adenocarcinoma, or leiomyosarcoma
Figure 1. Survival curves from the time at initial metastasectomy: influence of histologic type.
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(Table 2). In addition to the 12 cases of miscellaneous
histologic types, the 16 cases of choriocarcinoma were
excluded from the analysis because effective chemotherapy
was available for the latter cases. Variables for the multi-
variable analysis were as follows: combination of site and
histology, age, DFI, multiplicity of metastases, and tumor
size. After mutual adjustment, a short DFI of less than 12
months alone was related to risk of death.
Figure 2. Survival curves from the time at initial metastasectomy: influence of DFI. Log-rank test: P  .022.
Figure 3. Survival curves from the time at initial metastasectomy: influence of the number of resected tumors.
Log-rank test: P  .028.
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Discussion
The concept of metastasectomy is surgical tumor eradica-
tion that may contribute to prolonged survival. In general,
the indication for pulmonary metastasectomy includes the
following: the primary tumor is controlled or controllable;
there is no extrapulmonary disease; the medical status is
adequate to tolerate lung resection; complete resection is
possible; and no better treatment is available.9 A surgical
approach for selected patients has been regarded as benefi-
cial treatment, although almost all studies in the past were
retrospective and without a control group. The surgical
results after pulmonary metastasectomy of gynecologic can-
cers have also been published.3,10 Nevertheless, because
those reports contained a relatively small number of cases,
their data were inadequate to analyze the evidence of the
thoracic surgical procedure. Therefore, to analyze the clin-
ical, pathologic, and prognostic information of a large num-
ber of patients with pulmonary resection for metastatic
uterine malignancies, we conducted a retrospective study of
the patients enrolled in the Metastatic Lung Tumor Study
Group of Japan.
In cervical cancers, the most common site of extrapelvic
spread is the lung,11 and 80% to 90% of cervical cancers are
squamous cell carcinomas. Seki and colleagues12 reported a
5-year survival of 52% in 32 patients with cervical squa-
mous cell carcinoma who underwent pulmonary resection.
The survival data were similar to the present findings. The
survival of patients with cervical adenocarcinoma was com-
parable to the survival of patients with squamous cell car-
cinoma, although the number of patients was small. The
present results encourage surgery to improve survival for
highly selected patients with pulmonary metastases from
cervical adenocarcinoma.
In endometrial malignancies, Anderson and colleagues10
reported a median survival of 46 months in 6 patients with
TABLE 2. Relation between clinicopathologic characteris-
tics and survival: Multivariable analysis with Cox propor-
tional hazards model
Characteristic
Hazard
ratio 95% CI
P
value
Tumor histology
Cervical squamous cell carcinoma 1.00 Reference
Cervical adenocarcinoma 0.97 0.44-2.14 .98
Endometrial adenocarcinoma 0.50 0.20-1.21 .12
Leiomyosarcoma 1.11 0.37-3.36 .80
Age (y)
65 1.00 Reference
65 0.86 0.45-1.66 .68
Disease-free interval (mo)
12 1.00 Reference
1-11 2.26 1.06-4.78 .01
Number of resected metastases
4 1.00 Reference
1-3 0.60 0.27-1.32 .26
Tumor size (cm)
3.0 1.00 Reference
3.0 0.60 0.34-1.09 .10
CI, Confidence interval.
Figure 4. Survival curves from the time at initial metastasectomy: influence of resected tumor size. Log-rank test:
P  .014.
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endometrial adenocarcinoma who underwent pulmonary re-
section, and Otsuka and colleagues13 described a median
survival of 50 months in 5 patients. Survival of our 23
patients with endometrial adenocarcinoma was more favor-
able (5-year survival of 75.7%). However, these results may
be attributable to the patients’ backgrounds, that is, 18 of the
patients (78%) had less than 3 metastases, and 21 patients
(91%) underwent complete resection. Levenback and asso-
ciates14 documented a 5-year survival of 43% in 45 patients
with leiomyosarcoma, which was similar to the present
survival findings of patients with leiomyosarcoma and cer-
vical cancer.
Prognostic indicators to select patients who will benefit
from pulmonary metastasectomy have been analyzed for
various tumor types.15 The number of metastases, bilateral-
ity of lesions, DFI, and tumor doubling time are factors
generally associated with survival after surgical resection.
Shorter DFI or tumor doubling time may reflect tumor
aggressiveness and indicate poor postresection survival.16,17
The present analysis confirmed that a longer DFI (12
months) strongly influenced good postthoracotomy sur-
vival. However, limited to the patients with a single metas-
tasis, the group with a DFI of less than 12 months (n  16)
showed a 5-year survival of 48.6%. Therefore, a short DFI
should not preclude patients from pulmonary resection.
The optimum number of metastases in candidates for
surgery with curative intent was not clear. In the present
series, the patients with 3 or less metastases showed better
survival than those with more than 3 metastases, but this
was not significantly different in the multivariable analysis.
Limited to patients with a DFI of more than 12 months, the
present findings indicate that metastasectomy for multiple
lesions is effective to improve survival. Girard and associ-
ates18 investigated the surgical results of 44 patients with a
large number of pulmonary metastases and concluded that
the prognostic value depends on the resectability rather than
the number of metastases. They reported a 5-year survival
of 28% after metastasectomy for patients with 8 or more
lesions, which was not significantly different from the sur-
vival of patients with less than 8 lesions. After thorough
case-by-case selection of patients with a long DFI, pulmo-
nary metastasectomy may enable prolonged survival irre-
spective of the number of metastases.
Conclusion
It is recommended that patients with resectable lung metas-
tases from uterine malignancies undergo metastasectomy.
Carefully selected patients, especially those with a DFI of
more than 12 months, would have potential survival benefits.
We thank Satoshi Honjo, MD, Epidemiology Unit, Tochigi
Cancer Center, for statistical review.
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The following institutions participated in this study: Cancer Insti-
tute Hospital, Chiba Cancer Center, Chiba University, Hamamatsu
University, International Medical Center of Japan, Keio Univer-
sity, National Cancer Center, National Defense Medical College,
National Fuji Hospital, National Tokyo Medical Center, Nihon
University, Saitama Cancer Center, Saitama Medical School,
Tochigi Cancer Center, Toho University, Tokyo Medical Univer-
sity, Tokyo Metropolitan Komagome Hospital, and University of
Tokyo.
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